SNY:NSD-Sanofi ADR (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 58.74

Change

-0.61 (-1.03)%

Market Cap

USD 148.55B

Volume

1.89M

Analyst Target

USD 56.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-1.75 (-2.30%)

USD 228.18B
AMGN Amgen Inc

-8.47 (-2.59%)

USD 162.78B
GILD Gilead Sciences Inc

-2.78 (-2.37%)

USD 142.46B
BIIB Biogen Inc

-7.05 (-4.68%)

USD 20.57B
GRFS Grifols SA ADR

-0.07 (-0.90%)

USD 7.13B
AMRN Amarin Corporation PLC

+0.01 (+1.12%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLX Scilex Holding Company

-0.03 (-8.14%)

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing SNY

LIFE:CA Evolve Global Healthcare .. 5.28 % 0.69 %

-0.33 (-0.71%)

CAD 0.22B
HVAX:CA 4.85 % 0.00 %

N/A

N/A
GMOI The 2023 ETF Series Trust.. 2.15 % 0.00 %

-0.19 (-0.71%)

USD 0.06B
IBBQ Invesco Nasdaq Biotechnol.. 1.72 % 0.00 %

-0.19 (-0.71%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 1.71 % 0.00 %

-0.14 (-0.71%)

USD 0.52B
SYBD:F SSgA SPDR ETFs Europe I p.. 0.32 % 0.00 %

N/A

USD 0.84B
SEUC:SW SPDR® Bloomberg 0-3 Year.. 0.32 % 0.00 %

+0.19 (+-0.71%)

USD 0.88B
ADRD 0.00 % 0.26 %

N/A

N/A
ADRU 0.00 % 0.30 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-1.07 (-0.71%)

USD 0.06B
EUR:CA 0.00 % 0.66 %

N/A

N/A
PPH VanEck Pharmaceutical ETF 0.00 % 0.36 %

-1.17 (-0.71%)

USD 0.60B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.21 (-0.71%)

USD 0.52B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
SANE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.79% 80% B- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.79% 80% B- 92% A
Trailing 12 Months  
Capital Gain 21.21% 80% B- 81% B-
Dividend Return 4.20% 100% F 71% C-
Total Return 25.42% 90% A- 82% B
Trailing 5 Years  
Capital Gain 31.15% 57% F 54% F
Dividend Return 21.53% 100% F 64% D
Total Return 52.67% 57% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain 1.71% 70% C- 44% F
Dividend Return 5.45% 70% C- 51% F
Total Return 3.75% 100% F 75% C
Risk Return Profile  
Volatility (Standard Deviation) 11.47% 100% F 87% B+
Risk Adjusted Return 47.56% 80% B- 76% C+
Market Capitalization 148.55B 75% C 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector